A Phase 3 pivotal confirmatory lead-in study of REM-001 in patients with cutaneous metastatic breast cancer (CMBC)
Latest Information Update: 29 Nov 2023
At a glance
- Drugs Rostaporfin (Primary)
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- 13 Nov 2023 According to a Kintara Therapeutics media release, company is looking forward to enrolling the first patient in the 15 patient REM-001 study for cutaneous metastatic breast cancer.
- 09 Nov 2022 According to a Kintara Therapeutics media release, the company Paused the REM-001 program in Cutaneous Metastatic Breast Cancer (CMBC) to conserve cash which will be used to support the funding of the Company's ongoing international registrational study for VAL-083 in glioblastoma (GBM).
- 09 Nov 2022 Status changed from planning to withdrawn prior to enrolment, according to a Kintara Therapeutics media release.